Adjuvant treatment for esophagogastric junction cancer

Yukinori Kurokawa, Shuji Takiguchi, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu Nakajima, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalReview article

Abstract

Conducting clinical trials to establish evidence of the benefits of adjuvant treatment for resectable esophagogastric junction (EGJ) cancer is difficult because it is a very rare disease compared with gastric or esophageal cancer. In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer. Thus, this preoperative regimen is considered to be the standard adjuvant treatment for resectable EGJ cancer in the West. On the other hand, the Western evidence is not widely accepted in Asia because there are many differences in surgical techniques, particularly in the field of lymph node dissection, between the West and Asia. The standard adjuvant treatment for resectable EGJ cancer in Asia is postoperative chemotherapy using S-1 alone or capecitabine plus oxaliplatin based on the results of two large-scale phase III trials in gastric cancer conducted in East Asia. The incidence of EGJ cancer has recently increased in Japan, and nationwide studies to develop more effective adjuvant treatment for resectable EGJ cancer should be conducted in the near future.

Original languageEnglish
Pages (from-to)50-54
Number of pages5
JournalNihon Geka Gakkai zasshi
Volume116
Issue number1
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Esophagogastric Junction
Stomach Neoplasms
Neoplasms
oxaliplatin
Esophageal Neoplasms
Therapeutics
Far East
Carboplatin
Chemoradiotherapy
Rare Diseases
Paclitaxel
Lymph Node Excision
Japan
Clinical Trials
Drug Therapy
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kurokawa, Y., Takiguchi, S., Miyazaki, Y., Takahashi, T., Yamasaki, M., Miyata, H., ... Doki, Y. (2015). Adjuvant treatment for esophagogastric junction cancer. Nihon Geka Gakkai zasshi, 116(1), 50-54.

Adjuvant treatment for esophagogastric junction cancer. / Kurokawa, Yukinori; Takiguchi, Shuji; Miyazaki, Yasuhiro; Takahashi, Tsuyoshi; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Mori, Masaki; Doki, Yuichiro.

In: Nihon Geka Gakkai zasshi, Vol. 116, No. 1, 01.01.2015, p. 50-54.

Research output: Contribution to journalReview article

Kurokawa, Y, Takiguchi, S, Miyazaki, Y, Takahashi, T, Yamasaki, M, Miyata, H, Nakajima, K, Mori, M & Doki, Y 2015, 'Adjuvant treatment for esophagogastric junction cancer', Nihon Geka Gakkai zasshi, vol. 116, no. 1, pp. 50-54.
Kurokawa Y, Takiguchi S, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H et al. Adjuvant treatment for esophagogastric junction cancer. Nihon Geka Gakkai zasshi. 2015 Jan 1;116(1):50-54.
Kurokawa, Yukinori ; Takiguchi, Shuji ; Miyazaki, Yasuhiro ; Takahashi, Tsuyoshi ; Yamasaki, Makoto ; Miyata, Hiroshi ; Nakajima, Kiyokazu ; Mori, Masaki ; Doki, Yuichiro. / Adjuvant treatment for esophagogastric junction cancer. In: Nihon Geka Gakkai zasshi. 2015 ; Vol. 116, No. 1. pp. 50-54.
@article{12250b270978495cbff7c8a463e77ce1,
title = "Adjuvant treatment for esophagogastric junction cancer",
abstract = "Conducting clinical trials to establish evidence of the benefits of adjuvant treatment for resectable esophagogastric junction (EGJ) cancer is difficult because it is a very rare disease compared with gastric or esophageal cancer. In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer. Thus, this preoperative regimen is considered to be the standard adjuvant treatment for resectable EGJ cancer in the West. On the other hand, the Western evidence is not widely accepted in Asia because there are many differences in surgical techniques, particularly in the field of lymph node dissection, between the West and Asia. The standard adjuvant treatment for resectable EGJ cancer in Asia is postoperative chemotherapy using S-1 alone or capecitabine plus oxaliplatin based on the results of two large-scale phase III trials in gastric cancer conducted in East Asia. The incidence of EGJ cancer has recently increased in Japan, and nationwide studies to develop more effective adjuvant treatment for resectable EGJ cancer should be conducted in the near future.",
author = "Yukinori Kurokawa and Shuji Takiguchi and Yasuhiro Miyazaki and Tsuyoshi Takahashi and Makoto Yamasaki and Hiroshi Miyata and Kiyokazu Nakajima and Masaki Mori and Yuichiro Doki",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "116",
pages = "50--54",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "1",

}

TY - JOUR

T1 - Adjuvant treatment for esophagogastric junction cancer

AU - Kurokawa, Yukinori

AU - Takiguchi, Shuji

AU - Miyazaki, Yasuhiro

AU - Takahashi, Tsuyoshi

AU - Yamasaki, Makoto

AU - Miyata, Hiroshi

AU - Nakajima, Kiyokazu

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Conducting clinical trials to establish evidence of the benefits of adjuvant treatment for resectable esophagogastric junction (EGJ) cancer is difficult because it is a very rare disease compared with gastric or esophageal cancer. In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer. Thus, this preoperative regimen is considered to be the standard adjuvant treatment for resectable EGJ cancer in the West. On the other hand, the Western evidence is not widely accepted in Asia because there are many differences in surgical techniques, particularly in the field of lymph node dissection, between the West and Asia. The standard adjuvant treatment for resectable EGJ cancer in Asia is postoperative chemotherapy using S-1 alone or capecitabine plus oxaliplatin based on the results of two large-scale phase III trials in gastric cancer conducted in East Asia. The incidence of EGJ cancer has recently increased in Japan, and nationwide studies to develop more effective adjuvant treatment for resectable EGJ cancer should be conducted in the near future.

AB - Conducting clinical trials to establish evidence of the benefits of adjuvant treatment for resectable esophagogastric junction (EGJ) cancer is difficult because it is a very rare disease compared with gastric or esophageal cancer. In the West, where esophageal cancer occurs more frequently than gastric cancer, a phase III trial (the CROSS trial) demonstrated the efficacy of preoperative chemoradiotherapy using carboplatin plus paclitaxel for patients with esophageal or EGJ cancer. Thus, this preoperative regimen is considered to be the standard adjuvant treatment for resectable EGJ cancer in the West. On the other hand, the Western evidence is not widely accepted in Asia because there are many differences in surgical techniques, particularly in the field of lymph node dissection, between the West and Asia. The standard adjuvant treatment for resectable EGJ cancer in Asia is postoperative chemotherapy using S-1 alone or capecitabine plus oxaliplatin based on the results of two large-scale phase III trials in gastric cancer conducted in East Asia. The incidence of EGJ cancer has recently increased in Japan, and nationwide studies to develop more effective adjuvant treatment for resectable EGJ cancer should be conducted in the near future.

UR - http://www.scopus.com/inward/record.url?scp=84928701179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928701179&partnerID=8YFLogxK

M3 - Review article

C2 - 25842814

AN - SCOPUS:84928701179

VL - 116

SP - 50

EP - 54

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 1

ER -